Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Athenex, inc. save search
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 118.18%
H: 8.7%
C: -42.03%
quantum trial leap positive
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Published: 2022-12-20 (Crawled : 13:20) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 118.18%
H: 8.7%
C: -42.03%
quantum breast trial leap positive cancer
Athenex Announces Positive Results of Special Stockholder Meeting
Published: 2022-11-22 (Crawled : 16:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
meeting positive results
Athenex Announces Receipt of Positive Nasdaq Listing Determination
Published: 2022-11-03 (Crawled : 11:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.63%
H: 2.45%
C: 0.0%
nasdaq positive
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or ScalpEuropean Commission Decision Anticipated by July 2021
Published: 2021-05-21 (Crawled : 16:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis europe positive tirbanibulin chmp ema
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
Published: 2021-05-21 (Crawled : 14:00) - prnewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis positive tirbanibulin chmp
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp
Published: 2021-05-21 (Crawled : 14:00) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.04%
H: 1.85%
C: -1.85%
treatment actinic keratosis europe positive tirbanibulin chmp ema
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.